Name: Pfizer Inc. (NYSE:PFE) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Pfizer Inc., income statement, revenues

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Primary Care	30,589)	73,023)	52,029)	15,577)	—)
Specialty Care	14,970)	13,833)	15,194)	14,280)	—)
Oncology	11,627)	12,132)	12,333)	10,867)	—)
Global Biopharmaceuticals Business (Biopharma)	57,186)	98,988)	79,556)	40,724)	—)
Business Innovation	1,310)	1,342)	1,732)	927)	—)
Revenues	58,496)	100,330)	81,288)	41,651)	—)

Download chart

Item	Description	The company
Revenues	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Pfizer Inc. revenues increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.